October 19, 2025 a 06:00 pm
GILD: Fundamental Ratio Analysis - Gilead Sciences, Inc.
Gilead Sciences, Inc., a prominent player in the biopharmaceutical sector, showcases strong drug offerings across various medical needs, particularly in HIV/AIDS treatment and liver diseases. The company's collaborations and diverse product lineup maintain its competitive edge. However, market dynamics and regulatory changes can pose challenges.
Fundamental Rating
The current fundamental rating indicates that Gilead Sciences is performing well, with robust scores in critical financial aspects. However, the debt-to-equity ratio suggests a potential area for improvement.
| Category | Score | Visualization |
|---|---|---|
| Overall Score | 4 | |
| Discounted Cash Flow | 5 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 1 |
Historical Rating
The analysis of historical ratings shows a consistent performance with minor fluctuations. The past data supports current financial strength but highlights a similar area of improvement as the present.
| Date | Overall | DCF | ROE | ROA | Debt to Equity | Price to Earnings | Price to Book |
|---|---|---|---|---|---|---|---|
| 2025-10-17 | 4 | 5 | 5 | 5 | 1 | 3 | 1 |
| Previous | 0 | 5 | 5 | 5 | 1 | 3 | 1 |
Analyst Price Targets
Analyst consensus continues to show optimism in Gilead's stock potential, with price targets indicating significant upside opportunities. However, the range suggests varying assessments by different analysts.
| High | Low | Median | Consensus |
|---|---|---|---|
| $143 | $108 | $135 | $129.17 |
Analyst Sentiment
Analyst sentiment predominantly favors Gilead Sciences as a Buy, with a majority expressing confidence in the company's future growth prospects. Despite a few holds and sells, the consensus remains positive.
| Recommendation | Number | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 34 | |
| Hold | 22 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
In summary, Gilead Sciences shows solid financial health with promising future prospects as per analyst estimates. Its robust product portfolio and strategic partnerships underscore its market strength. However, its debt-to-equity ratio and some market uncertainties may impact future performance. Investors are advised to consider these factors when making investment decisions.